BIT Stock Overview
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biotron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.016 |
| Beta | -0.64 |
| 11 Month Change | -20.83% |
| 3 Month Change | -29.63% |
| 1 Year Change | -80.61% |
| 33 Year Change | -81.00% |
| 5 Year Change | -67.24% |
| Change since IPO | -95.73% |
Recent News & Updates
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Feb 27
We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth
Oct 20Recent updates
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Feb 27We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth
Oct 20We're Not Worried About Biotron's (ASX:BIT) Cash Burn
Jul 06Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jan 18Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jul 06Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation
Mar 17Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Nov 27Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
May 26We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Feb 10What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?
Dec 19Shareholder Returns
| BIT | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | 1.5% |
| 1Y | -80.6% | 10.0% | 17.2% |
Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: BIT underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| BIT volatility | |
|---|---|
| BIT Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: BIT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BIT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michelle Miller | www.biotron.com.au |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited Fundamentals Summary
| BIT fundamental statistics | |
|---|---|
| Market cap | AU$17.14m |
| Earnings (TTM) | -AU$3.44m |
| Revenue (TTM) | AU$1.65m |
10.4x
P/S Ratio-5.0x
P/E RatioIs BIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIT income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.65m |
| Other Expenses | AU$5.08m |
| Earnings | -AU$3.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0038 |
| Gross Margin | 100.00% |
| Net Profit Margin | -208.89% |
| Debt/Equity Ratio | 0% |
How did BIT perform over the long term?
See historical performance and comparison